Novo Nordisk to invest $1.09 billion to increase production in Brazil

Novo Nordisk Commits $1.12 Billion to Expand Ozempic Production in Brazil

Novo Nordisk, the Danish pharmaceutical leader, announced a R$6.4 billion ($1.12 billion) investment in its Montes Claros facility in Minas Gerais, Brazil. This expansion aims to double the plant’s size and enhance production capacity for diabetes and obesity treatments, including its blockbuster drugs Ozempic and Wegovy. The announcement, made on April 7, 2025, was attended […]

Novo Nordisk to invest $1.09 billion to increase production in Brazil

SAO PAULO (Reuters) -Novo Nordisk, the producer of Ozempic and other medications, announced on Monday a 6.4 billion reais ($1.09 billion) investment in Brazil to boost production. The investment aims to increase the manufacturing capacity at Novo Nordisk’s facility in Minas Gerais state of injectable drugs for the treatment of obesity, diabetes, and other serious chronic diseases, the company said in a statement. ($1 = 5.8721 reais) (Reporting b…

Novo Nordisk plans $1bn Brazil expansion - Global Construction Review

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its facility in Minas Gerais, southeast Brazil. The 74,000-sq-m project will be used for multiple products, including the GLP-1 hormone used in its diabetes treatment Ozempic. Brazil is one of Novo Nordisk’s five biggest markets and the company exports to 70 countries from there, Reuters reports. Reinaldo Costa, corporate vice pr…

The multinationals Novo Nordisk and Mercado Livre will make investments of R$ 6.4 billion and R$ 34 billion; Lula highlighted jobs The post Multinationals announce R$ 40 billion in investments in Brazil appeared first on Mercantile Monitor.

President Luiz Inácio Lula da Silva (PT) participated this Monday (April 7, 2025) in the event to announce the operational expansion of the pharmaceutical company Novo Nordisk – manufacturer of the drug Ozempic, created for the treatment of diabetes, but widely used for weight loss. The company announced an investment of R$6.4 billion to increase the production capacity of injectable treatments for people with obesity, diabetes and other serious…

The unit is strategic because it meets the Brazilian demand for insulin and GLP-1 analogs, in addition to exporting part of the volume produced to 70 countries